PODD Stock Analysis: Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetoot
- Latest close
- $149.68
- 20-day change
- +14.44%
- Trend state
- LEAN BEAR
- RSI 14
- 63.2
- Relative volume
- 0.72×
- 52W position
- 10.1%
- Market cap
- $10.4B
- Classification
- Healthcare · Medical - Devices
Research context, company dimensions and methodology
Market context
Insulet Corporation moved +14.44% over the latest 20-session window. BullRecon currently classifies the broader setup as LEAN BEAR.
Latest report
The latest cached company filing period (FY2025 · $2.7B revenue · $247.1M net income) is used alongside annual and quarterly history. Values remain tied to their reported period.
Six-dimension read
Quality is currently the strongest dimension at 5.3/6, while Value is the lowest at 3.9/6. Scores are comparative research signals, not forecasts.